Just caught Veracyte's Q4 numbers and they're pretty solid. Adjusted earnings came in at 53 cents per share, crushing expectations by over 30%. The stock popped 1.9% after hours when the report dropped.

What caught my eye is the revenue growth - hit $140.6 million for the quarter, up 18.5% year over year. Full year 2026 guidance shows they're expecting $570-582 million in revenues, which would be another 10-13% increase. Testing revenues are the real driver here, growing 14-16% according to their outlook.

The margins are expanding nicely too. Gross margin jumped to 74.4%, up over 5 percentage points from last year. Operating margin nearly tripled to 28.8%. Their testing business, especially Decipher and Afirma, keeps showing strong momentum with volume up 16% to around 45,500 tests. They also wrapped up migrating everything to their newer, more efficient v2 platform.

Cash position looks healthy - they're sitting on $362.6 million in cash, up from $239 million at the start of the year. Management says they're on track for sustained double-digit growth heading into 2026 across their cancer testing portfolio. Worth watching if you're looking at the biotech space.